Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for its drug AXN-2510 by the FDA, enabling the company to begin a phase 1 trial before the end of 2025. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback